The three cases with significant treatment-by-biomarker interaction in an RCT were cetuximab/KRAS and panitumumab/KRAS, both for metastatic colorectal cancer; and anastrozole/hormonal receptor for adjuvant treatment of early breast cancer. Here, KRAS is linked to breast carcinoma.